20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer (NSCLC)...
20:41 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest inhibiting GDF11 could help treat osteoporosis. In a mouse model of estrogen deficiency-induced bone loss, an anti-GDF11 mAb increased the number, thickness and volume of trabeculae in the distal femur metaphysis,...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Acceleron Pharma Inc preclinical data

In mice, twice-weekly 10 mg/kg subcutaneous ACE-2494 increased muscle mass from baseline to week 4 by 40.9% in the rectus femoris, 53.3% in the gastrocnemius and 86.9% in the pectoralis vs. vehicle-treated controls (p?0.01 for...
01:21 , Jun 20, 2014 |  BC Extra  |  Top Story

J&J Innovation inks new deals

Johnson & Johnson (NYSE:JNJ) announced 10 new deals out of its regional innovation centers. Among the deals, the London innovation center partnered with Minerva Neurosciences Inc. (Cambridge, Mass.) to develop MIN-202, an orexin 2 receptor...
07:00 , Jun 12, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Neurology; musculoskeletal disease Growth differentiation factor 11 (GDF11) Mouse studies suggest GDF11 could be useful for treating...
08:00 , Jan 13, 2014 |  BioCentury  |  Product Development

Niche play on TGF beta

Scholar Rock LLC's first disclosed deal provides a glimpse into how the company thinks it can exploit new structural biology insights about well-trodden growth factor targets to develop new therapies. The biotech has partnered with Johnson...
07:00 , Jun 13, 2013 |  BC Innovations  |  Targets & Mechanisms

Shrinking old hearts

Boston researchers have discovered a blood-borne protein, growth differentiation factor 11 , that can reverse age-related cardiac hypertrophy in mice.1 The protein could be used as a therapeutic agent once its long-term...
07:00 , Jun 6, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiomyopathy; heart failure Growth differentiation factor 11 (GDF11) Studies in mice suggest GDF11 could be...